Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
INM vs NMTC: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
INM Captures Overall Composite Edge (35.6 SELL vs 45.5 HOLD), While NMTC Leads 4–2 on Growth & Valuation Pillars
INM Overall Winner
6-Pillar Tally: INM 2 – 4 NMTC
Matrix Metrics: INM 3 – 4 NMTC
As of Nov 20, 2026, InMed Pharmaceuticals Inc. Common Shares (INM) captures the overall head-to-head institutional edge over NeuroOne Medical Technologies Corporation (NMTC) on higher Unified Composite conviction (35.6/100 SELL vs. 45.5/100 HOLD) after splitting the core matrix 3–4 (led by Profitability & Quality, R&D & Supply-Chain Moat), while NMTC wins 4–2 across the 6-pillar growth and valuation breakdown. INM trades at $15.56 (N/M Forward P/E, 0.0% operating margin) versus NMTC at $0.65 (N/M Forward P/E, -63.4% operating margin).
- Composite vs. Pillar Nuance: While NMTC currently prints a higher short-term Unified Composite Score (45.5/100 HOLD vs. INM 35.6/100 SELL), INM captures the overall institutional head-to-head verdict (3–4 matrix metrics and 2–4 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -63.4% operating margin) and revenue trajectory (-26.2% vs. +16.3% YoY).
- Technical & Structure Timing Caution: INM trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 99.3); meanwhile NMTC is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About INM vs NMTC
INM
Head-to-Head Winner
InMed Pharmaceuticals Inc. Common Shares
$15.56
+17.79% 1D
Market Cap
$7.3M
TTM Revenue
$4.9M
Forward P/E
N/M
Beta / 30D Vol
-20.85β · 2208% Vol
Unified Composite Score
35.6
SELL
Tech 15.0
Fund 32.0
Flow 50.0
Mom 40.0
Weinstein Technical Phase
Markup · Hold / add on dips
NMTC
NeuroOne Medical Technologies Corporation Common Stock
$0.65
-3.38% 1D
Market Cap
$6.1M
TTM Revenue
$12M
Forward P/E
N/M
Beta / 30D Vol
1.55β · 105% Vol
Unified Composite Score
45.5
HOLD
Tech 33.0
Fund 51.0
Flow 60.0
Mom 64.0
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (INM 2 – 4 NMTC)
1. Valuation Multiples
NMTC
Forward P/E
N/M
N/M
Trailing P/E
N/M
N/M
PEG Ratio
N/M
N/M
EV / Revenue
0.5x
0.3x
2. Growth & Scale
NMTC
Revenue Growth (YoY)
-26.2%
+16.3%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
$4.9M
$12M
Market Cap
$7.3M
$6.1M
3. Profitability & Quality
INM
Gross Margin
34.5%
23.0%
Operating Margin
0.0%
-63.4%
Net Profit Margin
0.0%
-59.7%
Return on Equity (ROE)
-222.1%
-124.7%
4. Balance Sheet & Cash Flow
NMTC
Cash Generation (TTM)
-$7.5M
-$7.6M
Cash Flow Margin
N/A
-60.7%
Net Cash / Leverage
$4.7M Net Cash
$2.6M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
NMTC
Options Structure Phase
UNCLASSIFIED
UNCLASSIFIED
Current IV / %ile
N/A (N/A)
N/A (N/A)
Put/Call OI Skew
N/A
N/A
OBV Trend / Tech Phase
NEUTRAL · Markup
NEUTRAL · Markdown
6. R&D & Supply-Chain Moat
INM
OpEx & R&D Intensity
34.5% of Rev ($1.7M)
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Drug Manufacturers - Specialty & Generic Operator
Medical Devices Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: INM (3) vs NMTC (4)| Institutional Metric | INM | NMTC | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $7.3M | $6.1M | Tie | |
| Trailing P/E Ratio | N/M | N/M | Tie | |
| Forward P/E Ratio | N/M | N/M | Tie | |
| Revenue Growth (YoY) | -26.2% | +16.3% | NMTC | |
| Operating Margin (TTM) | 0.0% | -63.4% | INM | |
| Net Profit Margin | 0.0% | -59.7% | INM | |
| Return on Equity (ROE) | -222.1% | -124.7% | NMTC | |
| 52-Week Range Position | 94% ($1–$16) | 2% ($1–$5) | INM | |
| Beta / 30D Volatility | -20.85β · 2208% Vol | 1.55β · 105% Vol | NMTC | |
| Unified Institutional Score | 35.6 / 100 (SELL) | 45.5 / 100 (HOLD) | NMTC | |
| Trailing 12M Revenue (USD) | $4.9M | $12M | Scale | |
| Gross Profit Margin (TTM) | 34.5% | 23.0% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 0.5x EV/Rev | N/M PEG · 0.3x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$7.5M ($4.7M Net Cash) | -$7.6M ($2.6M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
INM +1088.53 pp
3M Horizon
INM +1047.2 pp
6M Horizon
INM +2375.38 pp
1Y Horizon
INM +1125.54 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | INM Revenue | NMTC Revenue | INM Op. Margin | NMTC Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2012 | N/A | $0M | N/A | -1491.1% | NMTC |
| FY2013 | N/A | $0M | N/A | -2009.0% | NMTC |
| FY2014 | N/A | $0M | N/A | -4646.1% | NMTC |
| FY2021 | $0M | $0M | -535.9% | -5735.9% | INM |
| FY2022 | $0M | $0M | -1361.9% | -5860.2% | INM |
| FY2023 | $0M | $0M | -192.2% | -612.3% | INM |
| FY2024 | $0M | $0M | -166.9% | -344.3% | INM |
| FY2025 | $0M | $10M | -165.1% | -46.5% | NMTC |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
INM
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact INM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
NMTC
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact NMTC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
INM Moat Profile
Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
OpEx & R&D Reinvestment
34.5% of Rev ($1.7M)
90D Engineering Disclosures
0 Published
NMTC Moat Profile
Cyclical / Execution-Driven Positioning
Medical Devices Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ INM vs NMTC Key Questions & Quantitative Answers
As of Nov 20, 2026, InMed Pharmaceuticals Inc. Common Shares (INM) captures the overall head-to-head institutional edge over NeuroOne Medical Technologies Corporation (NMTC) on higher Unified Composite conviction (35.6/100 SELL vs. 45.5/100 HOLD) after splitting the core matrix 3–4 (led by Profitability & Quality, R&D & Supply-Chain Moat), while NMTC wins 4–2 across the 6-pillar growth and valuation breakdown. INM trades at $15.56 (N/M Forward P/E, 0.0% operating margin) versus NMTC at $0.65 (N/M Forward P/E, -63.4% operating margin). Composite vs. Pillar Nuance: While NMTC currently prints a higher short-term Unified Composite Score (45.5/100 HOLD vs. INM 35.6/100 SELL), INM captures the overall institutional head-to-head verdict (3–4 matrix metrics and 2–4 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -63.4% operating margin) and revenue trajectory (-26.2% vs. +16.3% YoY). Technical & Structure Timing Caution: INM trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 99.3); meanwhile NMTC is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
NMTC leads the Growth & Scale pillar: INM posts -26.2% YoY revenue growth and +0.0% YoY earnings growth on $4.9M TTM revenue (34.5% gross margin, 0.0% operating margin), compared with NMTC at +16.3% YoY revenue growth and +0.0% YoY earnings growth on $12M TTM revenue (23.0% gross margin, -63.4% operating margin). Across the 8-period historical trajectory (FY2012 to FY2025), INM cumulative revenue shifted N/A while NMTC shifted N/A. In operating R&D and SG&A reinvestment, INM deploys 34.5% of Rev ($1.7M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for NMTC.
NMTC screens cheaper on headline valuation multiples. INM trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.5x EV/Revenue (unreported FCF margin), whereas NMTC trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.3x EV/Revenue (-60.7% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against INM (-222.1% ROE) versus NMTC (-124.7% ROE) capital efficiency.
In options market volatility and institutional positioning, INM carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-20.85β · 2208% Vol realized risk). By comparison, NMTC carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.55β · 105% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
NMTC vs INM · Reverse Pair
INM vs NUWE
· Sector Peer
INM vs QNRX
· Sector Peer
INM vs REVB
· Sector Peer
NMTC vs IMMX
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma